Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intra-articular ART-I02 safety study in arthritis
NL-OMON45686Active, not recruiting
- Sponsor
- Arthrogen
- Start
- Apr 2018
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ART-I02 in rheumatoid arthritis (RA), osteoarthritis (OA) and arthritis, sponsored by Arthrogen. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Concomitant medication use and 3 more. Started Apr 2018; status: active, not recruiting.
02
Drugs
ART-I02
03
Conditions
rheumatoid arthritis (RA)osteoarthritis (OA)arthritis
Beyond the preview
Go deeper on NL-OMON45686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45686.